Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Lonitoclax in Relapsed/Refractory CLL, SLL, and Low-grade Lymphomas
NCT06708897Phase 1Recruiting
- Sponsor
- Lomond Therapeutics
- Start
- Apr 2025
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lonitoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL) and 1 more (12 arms), sponsored by Lomond Therapeutics. Primary endpoints: Incidence and severity of treatment-emergent adverse events and serious adverse events, Incidence of dose-limiting toxicities and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
lonitoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)marginal zone lymphoma (MZL)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on NCT06708897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708897.